Drug intelligence / Profile preview

genakumab

Development stage: Phase 4
Lead developer: Changchun GeneScience Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Genakumab is a monoclonal antibody that targets interleukin-1 beta (IL-1β). It is developed as an anti-inflammatory biologic agent for the treatment of inflammatory diseases. By specifically binding to IL-1β and inhibiting its interaction with its receptor, genakumab blocks downstream inflammatory signaling pathways. This mechanism rapidly and specifically inhibits inflammation associated with conditions such as acute gouty arthritis and systemic juvenile idiopathic arthritis. The drug is produced using genetic engineering techniques and has been developed in both powder and liquid formulations for subcutaneous administration[3][4][5].

Brand names: Genakumab injection
Other names: FirsekibartKinnazumab伏欣奇拜单抗

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on genakumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on genakumab.

Explore the full profile